|本期目录/Table of Contents|

[1]周 达,范建高.肠道菌群与肝脏疾病研究进展[J].传染病信息,2018,04:301-305.
 ZHOU Da,FAN Jian-gao*.Research progress in the correlation between gut microbiota and liver diseases[J].Infectious Disease Information,2018,04:301-305.
点击复制

肠道菌群与肝脏疾病研究进展(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2018年04期
页码:
301-305
栏目:
导向与述评
出版日期:
2018-08-30

文章信息/Info

Title:
Research progress in the correlation between gut microbiota and liver diseases
作者:
周 达范建高
200092,上海交通大学医学院附属新华医院消化内科(周达、范建高)
Author(s):
ZHOU Da FAN Jian-gao*
Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, 200092, China
关键词:
肠道菌群代谢产物脂肪肝肝硬化胆汁淤积发病机制治疗
Keywords:
gut microbiota metabolites fatty liver cirrhosis cholestasis pathogenesis treatment
分类号:
R575
DOI:
10.3969/j.issn.1007-8134.2018.04.002
文献标识码:
A
摘要:
肠道菌群被认为是人体的“特殊器官”,可通过肠- 肝轴介导多种肝脏疾病的发生发展。近年研究提示肠道菌群有望成为肝脏疾病诊治的靶标。本文就肠道菌群与肝脏疾病的研究进展作一综述。
Abstract:
The gut microbiota is considered to be a “special organ” of the human body, which can mediate the onset and development of liver diseases via gut-liver axis. Recent studies suggest that the gut microbiota may serve as a target for the diagnosis and treatment of liver diseases. This review mainly elucidates the progress of researches about the correlation between gut microbiota and liver diseases.

参考文献/References


[1] Lau LHS, Wong SH. Microbiota, obesity and NAFLD[J]. Adv Exp Med Biol, 2018, 1061:111-125.
[2] Ussar S, Griffin NW, Bezy O, et al. Interactions between gut microbiota, host genetics and diet modulate the predisposition to obesity and metabolic syndrome[J]. Cell Metab, 2015, 22(3):516-530.
[3] Mancini A, Campagna F, Amodio P, et al. Gut: liver: brain axis: the microbial challenge in the hepatic encephalopathy[J]. Food Funct, 2018, 9(3):1373-1388.
[4] 谢文瑞,何兴祥. 粪菌移植与慢性肝脏疾病[J]. 实用肝脏病杂志, 2017,20(6):651-653.
[5] Bashiardes S, Shapiro H, Rozin S, et al. Non-alcoholic fatty liver and the gut microbiota[J]. Mol Metab, 2016, 5(9):782-794.
[6] Ulluwishewa D, Anderson RC, McNabb WC, et al. Regulation of tight junction permeability by intestinal bacteria and dietary components[J]. J Nutr, 2011, 141(5):769-776.
[7] Kelly JR, Kennedy PJ, Cryan JF, et al. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders[J]. Front Cell Neurosci, 2015, 9:392.
[8] Zhou D, Pan Q, Xin FZ, et al. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier[J]. World J Gastroenterol, 2017, 23(1):60-75.
[9] Caesar R, Tremaroli V, Kovatcheva-Datchary P, et al. Crosstalk between gut microbiota and dietary lipids aggravates WAT inflammation through TLR signaling[J]. Cell Metab, 2015, 22(4):658-668.
[10] Cario E. Barrier-protective function of intestinal epithelial Tolllike receptor 2[J]. Mucosal Immunol, 2008, Suppl 1:S62-S66.
[11] Levy M, Thaiss CA, Zeevi D, et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling[J]. Cell, 2015, 163(6):1428- 1443.
[12] Sutterwala FS, Ogura Y, Flavell RA. The inflammasome in pathogen recognition and inflammation[J]. J Leukoc Biol, 2007, 82(2):259-264.
[13] Tan J, Mckenzie C, Potamitis M, et al. The role of short-chain fatty acids in health and disease[J]. Adv Immunol, 2014, 121:91- 119.
[14] Zhou D, Pan Q, Shen F, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J]. Sci Rep, 2017, 7(1): 1529.
[15] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia[J]. J Hepatol, 2017, 67(4):862-873.
[16] Ferolla SM, Couto CA, Costa-Silva L, et al. Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis[J]. Nutrients, 2016, 8(7):397.
[17] 杨蕊旭,周达,范建高. 靶向肠道菌群代谢产物防治非酒精性脂肪性肝病[J]. 实用肝脏病杂志,2017, 20(6):643-646.
[18] Gkolfakis P, Dimitriadis G, Traintafyllou K. Gut microbiota and non-alcoholic fatty liver disease [J]. Hepatobiliary Pancreat Dis Int, 2015, 14(6):572-581.
[19] Ilan Y. Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis[J]. World J Gastroenterol, 2012, 18(21):2609-2618.
[20] Jiang W, Wu N, Wang X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease[J]. Sci Rep, 2015, 5:8096.
[21] Ley RE, Backhed F, Turnbaugh P, et al. Obesity alters gut microbial ecology[J]. Proc Natl Acad Sci USA, 2005, 102(31):11070-11075.
[22] Mouzaki M, Comelli EM, Arendt BM, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease[J]. Hepatology, 传染病信息 2018 年8 月30 日 第31 卷 第4 期 Infect Dis Info, Vol. 31, No. 4, August 30, 2018 ·305· 2013, 58(1):120-127.
[23] Mehal WZ. The gordian knot of dysbiosis, obesity and NAFLD[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(11):637-644.
[24] Raman M, Ahmed I, Gillevet PM, et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2013, 11(7):868-875. E3.
[25] Gao X, Zhu Y, Wen Y, et al. Efficacy of probiotics in nonalcoholic fatty liver disease in adult and children: a metaanalysis of randomized controlled trials[J]. Hepatol Res, 2016, 46(12):1226-1233.
[26] Qamar AA. Probiotics in nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis[J]. J Clin Gastroenterol, 2015, 49(Suppl 1):S28-S32.
[27] Parnell JA, Raman M, Rioux KP, et al. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance[J]. Liver Int, 2012, 32(5):701-711.
[28] Lee SH. Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases[J]. Intest Res, 2015, 13(1):11-18.
[29] Kobyliak N, Virchenko O, Falalyeyeva T. Pathophysiological role of host microbiota in the development of obesity[J]. Nutr J, 2016, 15:43.
[30] He X, Ji G, Jia W, et al. Gut microbiota and nonalcoholic fatty liver disease: insights on mechanism and application of metabolomic[s J]. Int J Mol Sci, 2016, 17(3):300.
[31] Zhou R, Yazdi AS, Menu P, et al. A role for mitochondria in NLRP3 inflammasome activation[J]. Nature, 2011, 469(7329):221-225.
[32] Henao-Mejia J, Elinav E, Jin C, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity[J]. Nature, 2012, 482(7384):179-185.
[33] O’Connor S, Chouinard-Castonguay S, Gagnon C, et al. Prebiotics in the management of components of the metabolic syndrome[J]. Maturitas, 2017, 104:11-18.
[34] Cani PD, Lecourt E, Dewulf EM, et al. Gut microbiota fermentation of prebiotics increases satietogenic and incretin gut peptide production with consequences for appetite sensation and glucose response after a meal[J]. Am J Clin Nutr, 2009, 90(5):1236- 1243.
[35] Kirpich IA, Marsano LS, Mcclain CJ. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease[J]. Clin Biochem, 2015, 48(13-14):923-930.
[36] Ma X, Hua J, Li Z. Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells[J]. J Hepatol, 2008, 49(5):821-830.
[37] Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice[J]. Hepatology, 2009, 49(3):989-397.
[38] Haque TR, Barritt AS. Intestinal microbiota in liver disease[J]. Best Pract Res Clin Gastroenterol, 2016, 30(1):133-142.
[39] Alisi A, Bedogni G, Baviera G, et al. Randomised clinical trial: the beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis[J]. Aliment Pharmacol Ther, 2014, 39(11): 1276-1285.
[40] 骆庆玲,周永健. 粪菌移植治疗非酒精性脂肪性肝病研究与思考[J]. 实用肝脏病杂志,2017,20(6):647-650.
[41] Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia[J]. World J Hepatol, 2015, 7(3):425-442.
[42] Cirera I, Bauer TM, Navasa M, et al. Bacterial translocation of enteric organisms in patients with cirrhosis[J]. J Hepatol, 2001, 34(1):32-37.
[43] Bellot P, Frances R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications[J]. Liver Int, 2013, 33(1):31-39.
[44] Thalheimer U, Triantos CK, Samonakis DN, et al. Infection, coagulation, and variceal bleeding in cirrhosis[J]. Gut, 2005, 54(4):556-563.
[45] Zapater P, Francés R, González-Navajas JM, et al. Serum and ascitic fluid bacterial DNA: a new independent prognostic factor in noninfected patients with cirrhosis[J]. Hepatology, 2008, 48(6): 1924-1931.
[46] Bajaj JS, Betrapally NS, Hylemon PB, et al. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy[J]. Hepatology, 2015, 62(4):1260-1271.
[47] Chen Y, Ji F, Guo J, et al. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology[J]. Sci Rep, 2016, 6:34055.
[48] Sharma BC, Singh J. Probiotics in management of hepatic encephalopathy [J]. Metab Brain Dis, 2016, 31(6):1295-1301.
[49] Dhiman RK, Rana B, Agrawal S, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial[J]. Gastroenterology, 2014, 147(6):1327-1337.
[50] Doulberis M, Kotronis G, Gialamprinou D, et al. Non-alcoholic fatty liver disease: an update with special focus on the role of gut microbiota[J]. Metabolism, 2017, 71:182-197.
[51] Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: a randomized clinical trial[J]. Hepatology, 2017, 66(6):1727- 1738.
[52] Ren YD, Ye ZS, Yang LZ, et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy[J]. Hepatology, 2017, 65(5):1765-1768.
[53] Tang R, Wei Y, Li Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67(3):534-541.
[54] Sabino J, Vieira-Silva S, Machiels K, et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD[J]. Gut, 2016, 65(10):1681-1689.
[55] Kummen M, Holm K, Anmarkrud JA, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls[J]. Gut, 2017, 66(4):611-619.
[56] Iwasawa K, Suda W, Tsunoda T, et al. Characterisation of the faecal microbiota in Japanese patients with paediatric-onset primary sclerosing cholangitis[J]. Gut, 2017, 66(7):1344-1346.
[57] Bajaj JS, Kakiyama G, Zhao D, et al. Continued alcohol misuse in human cirrhosis is associated with an impaired gut-liver axis[J]. Alcohol Clin Exp Res, 2017, 41(11):1857-1865.
[58] Quraishi MN, Sergeant M, Kay G, et al. The gut-adherent microbiota of PSC-IBD is distinct to that of IBD[J]. Gut, 2017, 66(2):386-388.

备注/Memo

备注/Memo:
[ 基金项目] 国家科技部精准医学研究项目(2017YFC0908903);国家自然科学基金(81470840);上海市青年科技英才扬帆计划(18YF1415900) [ 作者单位] 200092,上海交通大学医学院附属新华医院消化内科(周达、范建高) [ 通信作者] 范建高,E-mail: fanjiangao@xinhuamed.com.cn
更新日期/Last Update: 2018-09-08